M&A / Deals

Pfizer bets up to $10.5B in 12-candidate cancer collab with China’s Innovent

BioSpace

Pfizer continues its dealmaking spree by striking a back-heavy partnership with China's Innovent Biologics to assemble a pipeline of antibody-based therapies for cancer.

Oncology

Read full story

pharminent May 29, 2026 (Last updated: May 29, 2026)

BioSpace

Pfizer continues its dealmaking spree by striking a back-heavy partnership with China’s Innovent Biologics to assemble a pipeline of antibody-based therapies for cancer.

Oncology

Read full story

Related Stories

Apogee investors riled by $1.3B royalty deal, as eczema drug matches Lilly’s Ebglyss

Eli Lilly to buy trio of vaccine developers in $3.8bn outlay

Gilead inks $140M API supply deal, tightening ties to Korean manufacturer

You May Have Missed

ASCO: BMS hails “compelling” phase 3 celmod readout

Summit’s PD-1/VEGF to take center stage at ASCO, with wide impact for peers

Pfizer bets up to $10.5B in 12-candidate cancer collab with China’s Innovent

Ahead of ASCO data drop, AZ gets key Imfinzi approval